Analyst Price Target is $83.50
▼ -13.76% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Novo Nordisk A/S in the last 3 months. The average price target is $83.50, with a high forecast of $120.00 and a low forecast of $36.25. The average price target represents a -13.76% upside from the last price of $96.82.
Current Consensus is
The current consensus among 6 polled investment analysts is to moderate buy stock in Novo Nordisk A/S. This Moderate Buy consensus rating has held steady for over two years.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.